ACHL Achilles Therapeutics plc

13.45
+0.42  (+3%)
Previous Close 13.03
Open 12.77
52 Week Low 12.51
52 Week High 18.9476
Market Cap $546,362,551
Shares 40,621,751
Float 40,621,751
Enterprise Value $367,569,415
Volume 13,848
Av. Daily Volume 102,853
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ATL001 - THETIS
Melanoma
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ATL001 - CHIRON
Non Small Cell Lung Cancer
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. - Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -

    - Completed initial public offering of ADSs raising $175.5 million in gross proceeds -        

    LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights.

    "Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating…

    - Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -

    - Completed initial public offering of ADSs raising $175.5 million in gross proceeds -        

    LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights.

    "Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating our precision TIL cNeT therapy in patients with non-small cell lung cancer and melanoma, respectively, and priced our successful US initial public offering on Nasdaq, which closed just after quarter-end," said Dr Iraj Ali, Chief Executive Officer of Achilles. "We continue to enroll and dose patients and have opened our first clinical sites in the US and EU. This year, we expect to report interim data from a total of ten patients that have received cNeT monotherapy across the CHIRON and THETIS trials and will also begin enrolling patients to receive higher dose cNeT. In addition, we will open Cohort B in the THETIS study to evaluate the addition of a PD-1 inhibitor to our cNeT therapy."

    Business Highlights

    • Received a recommendation from the Independent Data Safety Monitoring Committee to continue the ongoing Phase I/IIa CHIRON and THETIS trials as planned
    • Announced initial clinical data from the first six patients dosed with the Company's cNeT therapy showing encouraging evidence of cNeT engraftment, an overall tolerability profile similar to that of standard TIL products, stable disease in four out of the six patients, and one patient with tumor lesion reduction
    • Presented data at the American Association of Cancer Research (AACR) annual meeting detailing the Company's comprehensive translational research program and insights into the in vivo dynamics of cNeT post-dosing, and the potential to develop a potency-based release assay
    • Strengthened the Board of Directors and Scientific Advisory Board with the additions of Julie O'Neill and Markwin Velders, Ph.D., respectively, and continued to build the team in the UK & US, including key appointments across manufacturing, supply chain and clinical operations, bio-processing and intellectual property
    • Received a Horizon 2020 grant as part of the Neoantigen Consortium, with the aim of developing a tool to predict neoantigen immunogenicity.

    Financial Highlights

    • IPO: Priced an initial public offering of 9,750,000 ADRs at a public offering price of $18.00 per share for gross proceeds of $175.5 million. The IPO closed on April 6, 2021, after the quarter end.
    • Cash and cash equivalents: Cash and cash equivalents were $159.3 million as of March 31, 2021 as compared to $177.8 million as of December 31, 2020, not including $160.6 million in net proceeds from the IPO which closed on April 6, 2021. The Company anticipates that its existing cash and cash equivalents plus the IPO proceeds are sufficient to fund its planned operations into the second half of 2023, including full funding of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.
    • Operating Expenses: Operating Expenses were $13.7 million for the quarter ended March 31, 2021, which included $8.9 million in Research & Development, and General and Administrative expenses of $4.8 million.
    • Net loss: Net loss attributable to ordinary shareholders was $13.8 million for the quarter ended March 31, 2021 and the basic and diluted net loss per ordinary share was $8.38 for the quarter ended March 31, 2021.

    Upcoming Events

    • Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference at on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.
    • A poster detailing abstract TPS9138 entitled, An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Clonal Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON), will be presented at the 2021 ASCO Annual Meeting taking place virtually from June 4-9, 2021. Full abstracts will be released on May 19, 2021 at ASCO.org.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    Forward-Looking Statements

    This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Further information:

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000

    ACHILLES THERAPEUTICS PLC

    Condensed Consolidated Balance Sheets (Unaudited)

    (in thousands, except share and per share amounts)

    (expressed in U.S. Dollars, unless otherwise stated)

      March 31,  December 31, 
      2021  2020 
    ASSETS        
    Current assets:        
    Cash and cash equivalents $159,262  $177,849 
    Prepaid expenses and other current assets  14,058   9,948 
    Total current assets  173,320   187,797 
    Non-current assets:        
    Property and equipment, net  15,479   13,369 
    Operating lease right of use assets  14,155   14,740 
    Deferred tax assets  4   4 
    Other assets  3,145   3,008 
    Total non-current assets  32,783   31,121 
    TOTAL ASSETS $206,103  $218,918 
    LIABILITIES AND SHAREHOLDERS' EQUITY        
    Current liabilities:        
    Accounts payable $1,787  $6,314 
    Income taxes payable  19   7 
    Accrued expenses and other liabilities  8,646   6,590 
    Operating lease liabilities-current  4,610   3,712 
    Total current liabilities  15,062   16,623 
    Non-current liabilities:        
    Operating lease liabilities-non-current  11,329   12,271 
    Other long-term liability  659   652 
    Total non-current liabilities  11,988   12,923 
    Total liabilities  27,050   29,546 
    Commitments and contingencies (Note 11)        
    Shareholders' equity:        
    Ordinary shares, £0.001 par value; 30,853,489 and 4,389,920 shares

    authorized, issued and outstanding at March 31, 2021 and December

    31, 2020, respectively
      6   6 
    Deferred shares, £0.001 par value; 109,058 and 30,521 shares issued and

    outstanding as of March 31, 2021 and December 31, 2020, respectively
          
    Convertible preferred shares, £0.001 par value; no shares authorized,

    issued and outstanding as of March 31, 2021;104,854,673 shares

    authorized, issued and outstanding at December 31, 2020
      134   134 
    Additional paid in capital  236,305   234,922 
    Accumulated other comprehensive income  14,385   12,322 
    Accumulated deficit  (71,777)  (58,012)
    Total shareholders' equity  179,053   189,372 
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $206,103  $218,918 
             

    ACHILLES THERAPEUTICS PLC

    Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

    (in thousands, except share and per share amounts)

      Three Months Ended March 31, 
      2021  2020 
    OPERATING EXPENSES:        
    Research and development $8,876  $3,830 
    General and administrative  4,832   1,736 
    Total operating expenses  13,708   5,566 
    Loss from operations  (13,708)  (5,566)
    OTHER INCOME (EXPENSE), NET:        
    Other income (expense)  (45)  352 
    Total other income (expense), net  (45)  352 
    Loss before provision for income taxes  (13,753)  (5,214)
    Provision for income taxes  (12)   
    Net loss  (13,765)  (5,214)
    Other comprehensive income:        
    Foreign exchange translation adjustment  2,063   (6,510)
    Comprehensive loss $(11,702) $(11,724)
    Net loss per share attributable to ordinary shareholders—basic and diluted $(8.38) $(6.13)
    Weighted average ordinary shares outstanding—basic and diluted  1,641,938   850,377 
             



    Primary Logo

    View Full Article Hide Full Article
  2. LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumor neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.

    "Immunotherapy has revolutionized cancer treatment, providing survival benefits to patients with hard-to-treat tumors…

    LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumor neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.

    "Immunotherapy has revolutionized cancer treatment, providing survival benefits to patients with hard-to-treat tumors. There is an increasing call for personalized, precision therapies to induce immune responses against tumor-specific targets," said Dr Sergio Quezada, Chief Scientific Officer of Achilles. "This grant is a further validation of the work being done at Achilles by our team of world-class scientists. The contribution of our deep experience with neoantigen prediction algorithms and our innovative platform technology will allow the consortium to work toward identifying new immunotherapeutic targets and effective anticancer therapies."

    Current technologies struggle to discriminate immunogenic tumor neoantigens from the thousands of background mutations in tumors at scale. The consortium will work together to develop a high throughput neoantigen immunogenicity profiling platform. The project, named DECOD-Ag, will be conducted by a team of world-leading, interdisciplinary scientists from the consortium with expertise in cancer immunotherapy, bioinformatics, peptidomics, mass spectrometry, immune monitoring, clinical and translational medicine.

    This project has received €3 million ($3.6 million) from the European Union's Horizon 2020 research and innovation programme under the FETOPEN grant agreement number 964998. Approximately €0.8 million ($1 million) will be allocated to Achilles.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    About the Consortium Members

    UCL

    UCL is London's leading multidisciplinary university, with more than 13,000 staff and 42,000 students from 150 different countries. Through a progressive approach to teaching and research, our world leading academics, curious students and outstanding staff continually pursue excellence, break boundaries, and make an impact on real world problems. UCL is consistently ranked as one of the top performing organisations worldwide under the EU Framework Programmes for research.

    The Francis Crick Institute

    The Francis Crick Institute is a biomedical research institute located in London, UK. The Institute's ambition is to discover the fundamental biology underlying human health and diseases. The Institute's work helps to understand why disease develops and to find new ways to diagnose, prevent and treat a range of illnesses − such as cancer, heart disease, stroke, infections and neurodegenerative diseases. The Institute brings together outstanding scientists from all disciplines, carrying out research that will help improve the health and quality of people's lives, and keep the UK at the forefront of medical innovation.

    The Weizmann Institute of Science

    The Weizmann Institute of Science in Israel is one of the world's top-ranking multidisciplinary research institutions and offers masters' and doctoral-level degrees across five faculties, noted for its wide-ranging exploration of the natural and exact sciences. Institute scientists are advancing research on the human brain, artificial intelligence, computer science and encryption, astrophysics and particle physics, and they are tackling diseases such as cancer, and addressing climate change through environmental, ocean and plant sciences, and more.

    Technical University of Denmark

    DTU was founded in 1829 with the mission of creating value for the benefit of society. DTU is an international elite technical university where education, scientific advice, and innovation rest on a solid foundation of world-class research. The University is at the academic and multidisciplinary forefront of the technical and the natural sciences - with new initiatives in a number of demanding engineering disciplines such as life science.

    About Horizon 2020

    Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe's global competitiveness.

    By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

    For further information please visit: https://ec.europa.eu/programmes/horizon2020/.

    Forward-Looking Statements

    This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000



    Primary Logo

    View Full Article Hide Full Article
  3. LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.

    A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface…

    LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.

    A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    Further information:

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000

     



    Primary Logo

    View Full Article Hide Full Article
  4. LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces the appointment of Julie O'Neill as a Non-Executive Director to the Board and Markwin Velders, Ph.D. to its Scientific Advisory Board (SAB). Both individuals come to Achilles with strong track records of experience in cell therapy and cell therapy manufacturing.

    Ms. O'Neill is a business professional with more than two decades of executive experience in senior leadership roles. She was previously Executive Vice President, Global Operations at Alexion Pharmaceuticals. where she led the Global Operations business including product…

    LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces the appointment of Julie O'Neill as a Non-Executive Director to the Board and Markwin Velders, Ph.D. to its Scientific Advisory Board (SAB). Both individuals come to Achilles with strong track records of experience in cell therapy and cell therapy manufacturing.

    Ms. O'Neill is a business professional with more than two decades of executive experience in senior leadership roles. She was previously Executive Vice President, Global Operations at Alexion Pharmaceuticals. where she led the Global Operations business including product development, manufacturing, quality, supply chain and global real estate functions. Prior to joining Alexion, she was Vice President of Operations at Gilead Sciences.

    Ms. O'Neill serves as an Independent Director on the boards of ICON, DBV Technologies and Hookipa Pharma. She is also on the Board of Ireland's National Institute for Bioprocessing Research & Training (NIBRT) and serves as the Chairperson of the Strategic Advisory Board at the School of Pharmacy, Trinity College Dublin.

    "Achilles' precision T cell therapies have the potential to significantly benefit patients with melanoma, non-small cell lung cancer, as well as other solid tumor disease. As the Company gets closer to breaking ground on expanded manufacturing capacity for clinical and commercial use, operations, manufacturing and quality control are growing in importance," commented Julie O'Neill. "I am looking forward to joining the Achilles team and supporting them as they move along the clinical path. I am excited to be able to contribute at such an important stage in the company's development."

    The Company has also expanded its Scientific Advisory Board with the addition of Dr. Velders. He is the former VP, Operations and Managing Director at Kite Pharma EU. Before joining Kite, he was CSO at Dutch AM-Pharma, Business Unit Manager at TNO Biosciences, and CEO at SomantiX. After mediating the sale of the start-up T Cell Factory to Kite, he joined Kite Pharma to establish the company's EU headquarters in Amsterdam, helping to advance clinical development. Most recently, he was involved in the establishment of Kite's CAR-T commercial manufacturing site in Hoofddorp, The Netherlands.

    "Given the importance of manufacturing in cell therapy, we are delighted to welcome Julie to our Board and Markwin to our Scientific Advisory Board," said Iraj Ali, Chief Executive Officer at Achilles. "As we scale up our fully-closed and automated end-to-end manufacturing process for our expanding clinical work and eventual commercial production, their combined operations and manufacturing management expertise are a welcome complement to the capabilities of our current Board and team."

    Achilles has also announced that Rogier Rooswinkel, Ph.D. of Forbion has indicated that he will be resigning from the Board of Directors effective immediately prior to the date of the planned annual general meeting to be held on June 28, 2021.

    The members of the Achilles Therapeutics Board of Directors are now:

    Edwin Moses, Chairman

    Iraj Ali, Chief Executive Officer

    Carsten Boess, Non-Executive Director

    Derek DiRocco, Non-Executive Director

    Michael F. Giordano, Non-Executive Director

    Julie O'Neill, Non-Executive Director

    Rogier Rooswinkel, Non-Executive Director (until June 28, 2021)

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    Forward-Looking Statements

    This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Further information:

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

     

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000

     



    Primary Logo

    View Full Article Hide Full Article
  5. LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a patient case study from the Company's ongoing Phase I/IIa THETIS trial in metastatic or recurrent melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2021. Through a comprehensive translational research program, data from Patient T-05 offer insight into the in vivo dynamics of clonal neoantigen T cells (cNeT) post-dosing and the potential to develop a potency-based release assay.

    "As we move through our Phase I/IIa THETIS and CHIRON clinical programs in metastatic melanoma and advanced non-small cell lung cancer…

    LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a patient case study from the Company's ongoing Phase I/IIa THETIS trial in metastatic or recurrent melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2021. Through a comprehensive translational research program, data from Patient T-05 offer insight into the in vivo dynamics of clonal neoantigen T cells (cNeT) post-dosing and the potential to develop a potency-based release assay.

    "As we move through our Phase I/IIa THETIS and CHIRON clinical programs in metastatic melanoma and advanced non-small cell lung cancer, it is important to quantify and characterize cNeT, the active component in our precision T cell therapy, prior to and after cell infusion," said Dr Sergio Quezada, Chief Scientific Officer of Achilles. "The data from this case study show a polyclonal response and demonstrate our ability to establish product specificity, polyclonal reactivities, monitor persistence and expansion, as well as derive associations to efficacy. These are important differentiators of our technology that provide a mechanistic understanding of TIL therapy and potentially lend themselves to a reproducible potency assay."

    In a case study from the ongoing THETIS trial, a patient diagnosed with cutaneous melanoma received a three-cycle combination of ipilimumab and nivolumab which was stopped due to toxicity. In 2020, the patient had a recurrent lesion excised and cNeT manufactured through the VELOSTM process. The specificity and fitness of the cNeT were measured by flow cytometric analysis of IFN-γ and TNF-α cytokines, markers of T cell activity. Up to 53% of the T cells in the manufactured product were reactive to the patient's own clonal neoantigens following stimulation. cNeT can be tracked after dosing by using peptides that incorporate patient-specific clonal mutations from the tumor to stimulate cells from the blood of the patient. By using ELISpot technology to detect cNeT that produce cytokine in response to this stimulus, the expansion and persistence of cNeT in circulation can be calculated.

    Details of the poster presentation:

    Poster Title: Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research program

    Poster Number: 1508

    Poster Session Category / Title: Immunology / Adoptive Cell Therapy



    The poster and full session details can be found at www.aacr.org. The poster is also available in the Events & Presentations section of the Achilles website at https://ir.achillestx.com/events-and-presentations.

    About Achilles Therapeutics

    Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

    Forward-Looking Statements

    This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Lee M. Stern – VP, IR & External Communications

    +1 (332) 373-2634

    Consilium Strategic Communications

    Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

    +44 (0) 203 709 5000



    Primary Logo

    View Full Article Hide Full Article
View All Achilles Therapeutics plc News